Human NRG1-beta 1/HRG1-beta 1 DuoSet, 5 Plate

• Supplier: R&D Systems
• Catalog: DY377-05
• Category: ELISA Kit
• Assay Type: ELISA Development Kit
• Sample Type: 100 µL
• Gene: NRG1

Product References

Neuregulin-ErbB signaling promotes microglial proliferation and chemotaxis - Neuregulin-ErbB signaling promotes microglial proliferation and chemotaxis

Calvo M, Zhu N, Tsantoulas C, Ma Z, Grist J, Loeb JA, Bennett DL. J Neurosci. 2010 Apr 14;30(15):5437-50.

Neuregulin-1, the fetal endothelium, and brain damage in preterm newborns. - Neuregulin-1, the fetal endothelium, and brain damage in preterm newborns.

Hoffmann I, Bueter W, Zscheppang K, Brinkhaus MJ, Liese A, Riemke S, Dork T, Dammann O, Dammann CE. Brain Behav Immun. 2010 Jul;24(5):784-91.

HER2 phosphorylation is maintained by a PKB negative feedback loop in response to - HER2 phosphorylation is maintained by a PKB negative feedback loop in response to

Gijsen M, King P, Perera T, Parker PJ, Harris AL, Larijani B, Kong A. PLoS Biol. 2010 Dec 21;8(12):e1000563.

Preventive effects of heregulin-beta1 on macrophage foam cell formation and - Preventive effects of heregulin-beta1 on macrophage foam cell formation and

Xu G, Watanabe T, Iso Y, Koba S, Sakai T, Nagashima M, Arita S, Hongo S, Ota H, Kobayashi Y, Miyazaki A, Hirano T. Circ Res. 2009 Aug 28;105(5):500-10.

Neuregulin-1 beta is associated with disease severity and adverse outcomes in - Neuregulin-1 beta is associated with disease severity and adverse outcomes in

Ky B, Kimmel SE, Safa RN, Putt ME, Sweitzer NK, Fang JC, Sawyer DB, Cappola TP. Circulation. 2009 Jul 28;120(4):310-7.

Identification of biomarkers in human head and neck tumor cell lines that predict - Identification of biomarkers in human head and neck tumor cell lines that predict

Hickinson DM, Marshall GB, Beran GJ, Varella-Garcia M, Mills EA, South MC, Cassidy AM, Acheson KL, McWalter G, McCormack RM, Bunn PA, French T, Graham A, Holloway BR, Hirsch FR, Speake G. Clin Transl Sci. 2009 Jun;2(3):183-92.

Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in - Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in

Zhou BB, Peyton M, He B, Liu C, Girard L, Caudler E, Lo Y, Baribaud F, Mikami I, Reguart N, Yang G, Li Y, Yao W, Vaddi K, Gazdar AF, Friedman SM, Jablons DM, Newton RC, Fridman JS, Minna JD, Scherle PA. Cancer Cell. 2006 Jul;10(1):39-50.